Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q3 2023 · 10-Q
Revenue$7.40M$7.40M+110.4% vs Q3 2022 Net Income-$91.32M-$91.32MN/M vs Q3 2022 EPS Diluted-$1.64-$1.64N/M vs Q3 2022 Operating Income-$100,897,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$62,012,000N/M Margins · derivedOperating margin-1363.7%+1227.1 pt vs Q3 2022
Net margin-1234.3%+1090.7 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 2, 2023 · 33 d after period end